DISCLOSURE UNDER REGULATION 7(2) OF SEBI(PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Beryl Drugs Ltd has submitted a disclosure to BSE under SEBI's Prohibition of Insider Trading Regulations, 2015. The filing reveals that Sudhir Sethi, the main Promoter and Director of the company (DIN: 00090172), has acquired 7,500 shares of the company. This acquisition represents 0.14% of the total shareholding. The disclosure was made on March 25, 2026, as required by Regulation 7(2) when insiders trade in company shares. The accompanying Form C details the transaction specifics including pre- and post-acquisition shareholding balances for the promoter.
This is a routine insider trading compliance disclosure. The acquisition is very small (only 0.14%), so it is unlikely to have any meaningful impact on the stock price or shareholder value. It may signal minor insider confidence but does not indicate any major shift in promoter ownership.